证券代码：603014 证券简称：威高血净 公告编号：2025-049 山东威高血液净化制品股份有限公司 关于使用暂时闲置募集资金进行现金管理 到期赎回的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 山东威高血液净化制品股份有限公司（以下简称"威高血净"或"公司"）于 2025 年 5 月 27 日召开了第二届董事会第十一次会议和第二届监事会第八次会议，审议通 过了《关于使用部分暂时闲置募集资金进行现金管理的议案》，同意公司（含子公司， 下同）在确保不影响募集资金项目建设和募集资金使用的情况下，使用最高不超过 人民币 74,000 万元（含本数）的暂时闲置募集资金进行现金管理，增加公司收益， 为公司及股东获取投资回报。保荐机构对该事项发表了明确同意意见。具体内容详 见公司于 2025 年 5 月 28 日在上海证券交易所网站披露的《关于使用部分暂时闲置 募集资金进行现金管理的公告》（公告编号：2025-004）。 目前，公司部分闲置募集资金现金管理到期赎回，现将相关事项公告如下： 2025 年 8 月 25 日，公司使 ...

资料显示，山东威高血液净化制品股份有限公司位于山东省威海火炬高技术产业开发区威高西路7号， 成立日期2004年12月27日，上市日期2025年5月19日，公司主营业务涉及血液净化医用制品的研发、生 产和销售。主营业务收入构成为：耗材类77.55%，设备类18.25%，其他(补充)2.35%，其他1.85%。 12月1日，威高血净涨2.00%，成交额1.17亿元。两融数据显示，当日威高血净获融资买入额1226.45万 元，融资偿还1273.81万元，融资净买入-47.36万元。截至12月1日，威高血净融资融券余额合计1.53亿 元。 融资方面，威高血净当日融资买入1226.45万元。当前融资余额1.53亿元，占流通市值的9.42%。 融券方面，威高血净12月1日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量0.00股，融券余额0.00元。 责任编辑：小浪快报 截至9月30日，威高血净股东户数2.48万，较上期减少20.95%；人均流通股1535股，较上期增加 26.51%。2025年1月-9月，威高血净实现营业收入27.36亿元，同比增长3.45%；归母净利润3.41亿 ...

Core Viewpoint - The company has developed a "2025 Quality Improvement and Efficiency Enhancement Action Plan" aimed at optimizing operational efficiency, improving corporate governance, and enhancing investor returns, thereby driving high-quality development and increasing investment value [1][10]. Group 1: Business Focus and Market Strategy - The company focuses on the research, production, and sales of blood purification medical products, including hemodialyzers, dialysis tubing, dialysis machines, and peritoneal dialysis solutions, making it one of the most comprehensive manufacturers in the domestic market [1][2]. - The company aims to become a "global leader in comprehensive blood purification solutions," with sales covering over 6,000 medical institutions across all provinces and regions in China [1]. - The company is expanding its global market presence, particularly in Southeast Asia, South America, Eastern Europe, and North Africa, leveraging local production advantages to meet new customer demands [2]. Group 2: Corporate Governance - The company has established a governance structure that includes a shareholders' meeting, board of directors, and specialized committees, ensuring clear division of responsibilities and effective coordination [3]. - In response to regulatory changes, the company has revised several internal regulations to strengthen its governance framework and enhance sustainable development [3]. Group 3: Information Disclosure and Investor Relations - The company emphasizes high-quality information disclosure, adhering to relevant laws and regulations to ensure timely and accurate communication of its operational dynamics and value to the market [4]. - The company has established diverse communication channels to engage with investors, ensuring that their rights to information and participation are protected [4]. Group 4: Investor Returns - The company prioritizes reasonable returns for investors, implementing a cash dividend policy that aligns with long-term development and shareholder interests [5]. - For the mid-2025 dividend, the company plans to distribute 1.6 yuan (including tax) per 10 shares, totaling 65.82 million yuan, which accounts for 29.89% of the net profit for the period [5]. Group 5: Management of Key Personnel - The company maintains close communication with key stakeholders, including controlling shareholders and senior management, to enhance compliance awareness and responsibility [6]. - The company will continue to monitor regulatory changes and provide training to key personnel to ensure adherence to compliance standards and promote sustainable development [6].

证券代码：603014 证券简称：威高血净 公告编号：2025-046 山东威高血液净化制品股份有限公司 2025 年度"提质增效重回报"行动方案 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为深入贯彻落实国务院《关于进一步提高上市公司质量的意见》要求，积极响 应上海证券交易所《关于开展沪市公司"提质增效重回报"专项行动的倡议》，山东 威高血液净化制品股份有限公司（以下简称"公司"）结合自身实际经营情况、发展 战略及财务状况，基于对未来持续稳定发展的信心和对公司价值的认可，制定了 《2025 年度"提质增效重回报"行动方案》（以下简称"行动方案"），旨在持续优化 经营效率、完善公司治理、强化投资者回报，不断增强核心竞争力，推动公司高质 量发展与投资价值提升，切实保护投资者尤其是中小投资者的合法权益。本次行动 方案已于 2025 年 12 月 1 日经公司第二届董事会第十九次会议审议通过，具体内容 如下： 一、聚焦主营业务，推动公司经营提质增效 公司始终专注于血液净化医用制品的研发、生产和销售，主要产品血液透析器、 血液透析 ...

证券代码：603014 证券简称：威高血净 公告编号：2025-048 山东威高血液净化制品股份有限公司 二、董事会会议审议情况 经与会董事审议，并对议案进行了投票表决，通过了以下决议： （一）审议通过了《关于 2025 年度"提质增效重回报"行动方案的议案》 具体内容详见公司同日刊登于上海证券交易所网站（www.sse.com.cn）及公司指 定信息披露媒体的《山东威高血液净化制品股份有限公司 2025 年度"提质增效重回 报"行动方案》。 表决结果：9 票同意，0 票弃权，0 票反对。 特此公告。 山东威高血液净化制品股份有限公司董事会 第二届董事会第十九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 山东威高血液净化制品股份有限公司（以下简称"威高血净"或"公司"）第二届董 事会第十九次会议于 2025 年 12 月 1 日以现场和通讯相结合的方式在公司会议室召 开，会议通知于 2025 年 11 月 27 日通过通讯方式送达全体董事。本次会议由董事长 宋修山召集并主持，会议应出席 ...

Core Viewpoint - The article discusses the blood purification device industry, highlighting the increasing prevalence of End-Stage Renal Disease (ESRD) and the growth potential of blood purification technologies in response to this global health challenge [18][21]. Market Overview - The global ESRD patient population is projected to grow from 91.33 million in 2019 to 148.51 million by 2030, with a CAGR of 4.2% [18][19]. - In China, the ESRD patient population is expected to increase from 3.025 million in 2019 to 6.132 million by 2030, with a CAGR of 5.8% [20][18]. Treatment Methods - Blood purification is the most widely used treatment for ESRD, offering higher survival rates compared to kidney transplantation and conservative treatment [21]. - The number of patients receiving blood purification treatment in China rose from 736,000 in 2019 to 1.069 million in 2023, with a CAGR of 9.8%, and is expected to reach 3.791 million by 2030, with a CAGR of 19.8% [21][23]. Blood Purification Technologies - The main blood purification methods include hemodialysis, peritoneal dialysis, blood perfusion, and blood filtration, with hemodialysis being the most mature and widely applied [29]. - Hemodialysis effectively removes harmful substances and excess fluid from the blood, making it suitable for patients at various disease stages [29]. Market Size and Growth - The Chinese blood dialysis device market is projected to grow from CNY 11.63 billion in 2019 to CNY 51.52 billion by 2030, with a CAGR of 19.9% from 2023 to 2030 [30][28]. - The market share of blood dialysis devices in China is expected to see significant growth, with specific segments like blood dialysis machines and consumables also experiencing robust growth rates [30]. Competitive Landscape - Domestic companies are rapidly catching up with international competitors in the blood purification consumables sector, achieving nearly 50% market share in dialysis filters [31]. - The competitive landscape for blood dialysis machines is evolving, with domestic manufacturers improving their technology and performance to match imported products [37][33]. Policy and Market Dynamics - The article notes that the Chinese government has been implementing centralized procurement policies, leading to significant price reductions and accelerating the domestic replacement process in the blood purification market [36][35].

Investment Rating - The report does not explicitly provide an investment rating for the blood purification device industry Core Insights - The report highlights the increasing prevalence of End-Stage Renal Disease (ESRD) globally and in China, with the number of patients expected to rise significantly by 2030, indicating a growing market for blood purification devices [13][15] - Blood purification is identified as the most widely used treatment method for ESRD, with a higher survival rate compared to other treatments like kidney transplantation and conservative treatment [19] - The Chinese blood purification device market is projected to grow rapidly, driven by an increase in ESRD patients, improved reimbursement policies, and advancements in dialysis infrastructure [26] Market Overview - The global ESRD patient population increased from 9.13 million in 2019 to 11.14 million in 2023, with a CAGR of 5.1%, and is expected to reach 14.85 million by 2030 [13][14] - In China, the ESRD patient population grew from 3.03 million in 2019 to 4.13 million in 2023, with a CAGR of 8.1%, projected to reach 6.13 million by 2030 [15] - The number of patients receiving blood purification treatment in China rose from 736,000 in 2019 to 1.07 million in 2023, with a CAGR of 9.8%, expected to reach 3.79 million by 2030 [19][18] Treatment Methods - Blood purification methods include hemodialysis, peritoneal dialysis, blood perfusion, and blood filtration, with hemodialysis being the most common and effective method for ESRD patients [23] - Hemodialysis is noted for its effectiveness in removing toxins and excess fluid, while peritoneal dialysis is gaining traction due to its home treatment capabilities [21][23] Market Size and Growth - The Chinese blood purification device market size increased from 116.3 billion yuan in 2019 to 145.0 billion yuan in 2023, with a CAGR of 5.7%, and is expected to reach 515.2 billion yuan by 2030, with a projected CAGR of 19.9% from 2023 to 2030 [26] - The market for blood purification devices is segmented into blood purification machines, blood purification consumables, and other related equipment, with significant growth expected across all segments [26] Competitive Landscape - Domestic companies are rapidly catching up to international competitors in the blood purification consumables market, achieving nearly 50% market share in key areas [27] - The report indicates that the domestic market for blood purification machines still has room for growth, as these products have historically relied on imports due to high technical barriers [27][34] - The report emphasizes that domestic manufacturers are improving their technology and performance, positioning themselves to capture a larger market share [29][34]

证券代码：603014 证券简称：威高血净 公告编号：2025-046 山东威高血液净化制品股份有限公司 关于发行股份购买资产暨关联交易事项的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 自本次交易预案披露以来，公司及相关各方积极推进本次交易的各项工作。截 至本公告披露日，本次交易涉及的审计、评估、尽职调查等工作正按照计划开展。 待相关工作完成后，公司将再次召开董事会审议本次交易的相关事项。 公司将根据本次交易工作的进展情况，严格按照《上市公司重大资产重组管理 办法》《上海证券交易所上市公司自律监管指引第 6 号——重大资产重组》等法律 法规和规范性文件的有关规定，及时履行信息披露义务。 四、风险提示 本次交易尚需公司董事会再次审议及公司股东会审议批准，并获得有权监管机 构批准、核准、注册或同意后方可正式实施；本次交易能否取得相关批准、核准、 注册或同意，以及最终取得的时间均存在不确定性，有关信息均以公司指定信息披 露媒体发布的公告为准。敬请广大投资者关注后续公告并理性投资，注意投资风险。 特此说明。 一、本次交易 ...

威高血净公告称，公司正筹划发行股份购买威高普瑞100%股权，预计构成重大资产重组和关联交易， 不构成重组上市。公司股票于2025年10月20日开市起停牌，11月3日开市起复牌。截至公告披露日，交 易涉及的审计、评估等工作正按计划开展，待完成后将再次召开董事会审议。本次交易尚需公司董事 会、股东会审议及监管机构批准，存在不确定性。 ...

Core Viewpoint - The company, Shandong Weigao Blood Purification Products Co., Ltd., is actively expanding its overseas business and is involved in a significant asset restructuring transaction to acquire 100% of Weigao Puri Pharmaceutical Packaging Co., Ltd. [2][3] Company Overview - Shandong Weigao Blood Purification Products Co., Ltd. specializes in the research, production, and sales of blood purification medical products, including hemodialysis devices, dialysis tubing, dialysis machines, and peritoneal dialysis solutions [2][3][7] - The company was established on December 27, 2004, and went public on May 19, 2025 [3][7] - As of September 30, 2025, the company reported a revenue of 2.736 billion yuan, a year-on-year increase of 3.45%, and a net profit attributable to shareholders of 341 million yuan, up 7.92% year-on-year [7][8] Market Activity - On November 28, the stock price of Weigao Blood Purification increased by 1.13%, with a trading volume of 75.5524 million yuan and a turnover rate of 4.74%, bringing the total market capitalization to 16.890 billion yuan [1] - The company is categorized under the medical device sector, specifically focusing on medical consumables, with a revenue composition of 77.55% from consumables, 18.25% from equipment, and 2.35% from other sources [7] Strategic Initiatives - The company is focusing on expanding its international presence, particularly in Southeast Asia, South America, Eastern Europe, and North Africa, with subsidiaries already established in Ecuador and Indonesia [2] - The planned acquisition of Weigao Puri is expected to enhance the company's product offerings and market position, while not affecting the actual control of the company [3]